A large Korean study showed elevated uveitis recurrence rates following Covid-19 vaccination, with the Janssen vaccine (Ad26.COV2.S) more than doubling patients’ risk.
Researchers at Hanyang University assessed the effects of the Janssen, Pfizer BioNTech, Moderna mRNA-1273 and AstraZeneca ChAdOx1 vaccines on 543,737 individuals with a history of uveitis. They found a cumulative incidence of post-vaccination uveitis of 8.6% at three months, 12.5% at six months and 16.8% at one year, predominantly of the anterior type. They advised clinicians treating individuals with a history of uveitis to consider the potential risk of uveitis recurrence in vaccination strategies and clinical monitoring.
In separate news, AstraZeneca announced it has withdrawn its UK-developed Covid-19 vaccine, citing lack of demand.
